# Tipifarnib in Subjects With Myelodysplastic Syndromes

> **NCT02779777** · PHASE2 · TERMINATED · sponsor: **Kura Oncology, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT02779777
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-01
- **Primary completion:** 2018-08-28
- **Final completion:** 2018-08-28
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779777, "Tipifarnib in Subjects With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02779777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*